BG105582A - Перли с контролирано освобождаване, метод за получаването им и включваща ги лекарствена форма - Google Patents

Перли с контролирано освобождаване, метод за получаването им и включваща ги лекарствена форма

Info

Publication number
BG105582A
BG105582A BG105582A BG10558201A BG105582A BG 105582 A BG105582 A BG 105582A BG 105582 A BG105582 A BG 105582A BG 10558201 A BG10558201 A BG 10558201A BG 105582 A BG105582 A BG 105582A
Authority
BG
Bulgaria
Prior art keywords
controlled release
layer
producing
release bead
same
Prior art date
Application number
BG105582A
Other languages
English (en)
Other versions
BG65149B1 (bg
Inventor
Torkel Gren
Anders Ringberg
Martin Wikberg
Randy Wald
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG105582(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of BG105582A publication Critical patent/BG105582A/bg
Publication of BG65149B1 publication Critical patent/BG65149B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

Перлите с контролирано отделяне включват сърцевинна единица от по същество водоразтворим или водонабъбващ инертен материал, първи слой върху сърцевинната единица от по същество водонеразтворим полимер, втори слой, покриващ първия слой и съдържащ една активна съставка, и трети слой от полимер върху втория слой, ефективен за контролираното освобождаване на активната съставка. Първият слой се адаптира да контролира навлизането на вода в сърцевината. Изобретението се отнася и до метод за получаванена перлите с контролирано освобождаване.
BG105582A 1998-11-11 2001-06-08 Перли с контролирано освобождаване, метод за получаването им и включваща ги лекарствена форма BG65149B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (2)

Publication Number Publication Date
BG105582A true BG105582A (bg) 2001-12-29
BG65149B1 BG65149B1 (bg) 2007-04-30

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105582A BG65149B1 (bg) 1998-11-11 2001-06-08 Перли с контролирано освобождаване, метод за получаването им и включваща ги лекарствена форма

Country Status (40)

Country Link
US (1) US6911217B1 (bg)
EP (1) EP1128819B1 (bg)
JP (1) JP3616011B2 (bg)
KR (1) KR100467384B1 (bg)
CN (1) CN1169522C (bg)
AP (1) AP1323A (bg)
AR (1) AR027815A1 (bg)
AT (1) ATE247458T1 (bg)
AU (1) AU762410B2 (bg)
BG (1) BG65149B1 (bg)
BR (1) BRPI9915142B8 (bg)
CA (1) CA2350061C (bg)
CZ (1) CZ299582B6 (bg)
DE (1) DE69910604T2 (bg)
DK (1) DK1128819T3 (bg)
EA (1) EA005074B1 (bg)
EE (1) EE05232B1 (bg)
ES (1) ES2204193T3 (bg)
GE (1) GEP20022833B (bg)
HK (1) HK1040917B (bg)
HR (1) HRP20010333B1 (bg)
HU (1) HU226582B1 (bg)
ID (1) ID30039A (bg)
IL (1) IL142809A0 (bg)
IS (1) IS2370B (bg)
MA (1) MA25325A1 (bg)
MY (1) MY122195A (bg)
NO (1) NO331399B1 (bg)
NZ (1) NZ511430A (bg)
OA (1) OA11673A (bg)
PL (1) PL195780B1 (bg)
PT (1) PT1128819E (bg)
RS (1) RS49891B (bg)
SE (1) SE9803871D0 (bg)
SI (1) SI1128819T1 (bg)
SK (1) SK284758B6 (bg)
TW (2) TWI222879B (bg)
UA (1) UA57165C2 (bg)
WO (1) WO2000027364A1 (bg)
ZA (1) ZA200103575B (bg)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
CN100353935C (zh) * 1999-11-11 2007-12-12 法马西雅公司 含托特罗定的药物制剂及其应用
MXPA05002302A (es) * 2002-08-28 2005-06-08 Pharmacia Corp Composicion liquida oral de tolterodina.
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
MXPA05007767A (es) * 2003-01-22 2006-01-31 Pfizer Health Ab Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios.
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ATE493981T1 (de) 2003-11-04 2011-01-15 Supernus Pharmaceuticals Inc Einmal tägliche dosierformen von trospium
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
EP1836156A1 (en) * 2005-01-10 2007-09-26 Teva Gyogyszergyar Reszvenytarsasag Substantially pure tolterodine tartrate and process for preparing thereof
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
WO2006130187A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic lactobacilli
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8298574B2 (en) 2006-01-18 2012-10-30 Intec Pharma Ltd. Method and apparatus for forming delivery devices for oral intake of an agent
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
KR20080099334A (ko) * 2006-02-24 2008-11-12 테바 파마슈티컬 인더스트리즈 리미티드 메토프로롤 숙시네이트 서방정 및 이의 제조 방법
MX2008011952A (es) * 2006-03-21 2008-10-01 Teva Pharma Formulacion de liberacion controlad de tolterodina.
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
CN101453993A (zh) * 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
WO2007122015A1 (en) * 2006-04-21 2007-11-01 Synthon B.V. Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
ES2497494T3 (es) 2006-06-21 2014-09-23 Opko Renal, Llc Método de tratamiento y prevención del hiperparatiroidismo secundario
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
MX2009005478A (es) 2006-11-27 2009-08-12 Lundbeck & Co As H Derivados de heteroarilamida.
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
US20090017111A1 (en) * 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
WO2009140557A2 (en) * 2008-05-14 2009-11-19 Capricorn Pharma, Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
AU2010277207B2 (en) * 2009-07-31 2014-06-26 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
JP5736031B2 (ja) 2010-03-29 2015-06-17 フェリング ベスローテン フェンノートシャップ 速溶解性医薬組成物
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120289560A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
AU2012307530B2 (en) 2011-09-16 2016-12-08 Ferring B.V. A fast dissolving pharmaceutical composition
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
AU2013289403B2 (en) 2012-07-12 2017-05-11 Ferring B.V. Diclofenac formulations
WO2014047477A2 (en) * 2012-09-20 2014-03-27 Sks Ocular, Llc Multilayer biodegradable microparticles for sustained release of therapeutic agents
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
WO2014159051A1 (en) * 2013-03-13 2014-10-02 Advanced Bionutrition Corp. Stable bioactive substances and methods of making
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
EP3193925A2 (en) 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA3018328A1 (en) * 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3431107A4 (en) * 2016-02-23 2019-11-13 Nipro Corporation PARTICULARS OF A PHARMACEUTICAL COMPOSITION AND MOUTH-DISTURBING PREPARATION THEREOF
IL290855B1 (en) 2016-03-28 2024-02-01 Eirgen Pharma Ltd Treatment methods using vitamin D

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
TWI222879B (en) 2004-11-01
AP2001002166A0 (en) 2001-06-30
EA200100538A1 (ru) 2001-10-22
AR027815A1 (es) 2003-04-16
BRPI9915142B8 (pt) 2021-05-25
MA25325A1 (fr) 2001-12-31
DE69910604D1 (de) 2003-09-25
EE05232B1 (et) 2009-12-15
KR100467384B1 (ko) 2005-01-24
NZ511430A (en) 2003-05-30
DE69910604T2 (de) 2004-06-24
BR9915142A (pt) 2001-08-07
CA2350061A1 (en) 2000-05-18
OA11673A (en) 2005-01-12
HUP0105038A3 (en) 2006-07-28
EA005074B1 (ru) 2004-10-28
CZ299582B6 (cs) 2008-09-10
JP3616011B2 (ja) 2005-02-02
UA57165C2 (uk) 2003-06-16
NO331399B1 (no) 2011-12-19
AU1436600A (en) 2000-05-29
EP1128819B1 (en) 2003-08-20
IS5936A (is) 2001-05-09
DK1128819T3 (da) 2003-12-01
BRPI9915142B1 (pt) 2015-08-25
CN1169522C (zh) 2004-10-06
MY122195A (en) 2006-03-31
SI1128819T1 (en) 2003-12-31
WO2000027364A1 (en) 2000-05-18
TWI267385B (en) 2006-12-01
NO20012314L (no) 2001-07-09
SK284758B6 (sk) 2005-11-03
PL348612A1 (en) 2002-06-03
KR20010075695A (ko) 2001-08-09
SK6252001A3 (en) 2002-01-07
AP1323A (en) 2004-11-05
HK1040917A1 (en) 2002-06-28
EP1128819A1 (en) 2001-09-05
JP2003517446A (ja) 2003-05-27
PT1128819E (pt) 2003-12-31
HRP20010333A2 (en) 2003-04-30
NO20012314D0 (no) 2001-05-10
RS49891B (sr) 2008-08-07
ZA200103575B (en) 2002-05-03
HU226582B1 (en) 2009-04-28
ID30039A (id) 2001-11-01
IL142809A0 (en) 2002-03-10
AU762410B2 (en) 2003-06-26
HUP0105038A2 (en) 2002-06-29
HRP20010333B1 (en) 2004-10-31
CZ20011627A3 (cs) 2001-10-17
EE200100254A (et) 2002-12-16
PL195780B1 (pl) 2007-10-31
CA2350061C (en) 2005-05-17
IS2370B (is) 2008-06-15
BG65149B1 (bg) 2007-04-30
HK1040917B (zh) 2005-05-27
YU33101A (sh) 2003-10-31
ES2204193T3 (es) 2004-04-16
ATE247458T1 (de) 2003-09-15
SE9803871D0 (sv) 1998-11-11
US6911217B1 (en) 2005-06-28
GEP20022833B (en) 2002-11-25
CN1326339A (zh) 2001-12-12

Similar Documents

Publication Publication Date Title
BG105582A (bg) Перли с контролирано освобождаване, метод за получаването им и включваща ги лекарствена форма
MXPA02004574A (es) Formulacion farmaceutica que contiene tolterodina y su uso.
DE59507193D1 (de) VERFAHREN ZU hERSTELLUNG EINER MANTELTABLETTE MIT SPITZEM KERN
AU4540396A (en) New stable ganelic formulations containing an acid-labile benzimidazol compound, and production process
AU2684497A (en) Biodegradable sustained-release preparation, biodegradable pheromone dispenser and biodegradable pest controlling agent
CA2338070A1 (en) Diltiazem controlled release formulation and method of manufacture
AU8109398A (en) Implants for controlled release of pharmaceutically active principles and method for making same
AU4464897A (en) Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix
AU3169995A (en) Composition providing selective release of an active ingredient
EP0741109A3 (en) Method and composition for enhancing biocidal activity
AU7569796A (en) Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds.
AU7036198A (en) Improved method for producing thiazolidinediones, and new thiazolidinediones
AU5320998A (en) Microparticles containing active substances, agents containing the same, their use in ultrasound-controlled releasing of active substances as well as the method for their production
AU692030B2 (en) Hydantoin derivatives, process for producing the same and herbicides comprising the same as active ingredients
AU7022694A (en) Ester compound, active agent for controlling noxious insect pests containing the same as active ingredient, alcohol compound for production of the ester compound and process for producing the alcohol compound
EG20432A (en) Solid crop protection formulation which comprises polyvinylpyrrolidone and pyrethroid insecticide
AU1092095A (en) Intra-uterine ring for the release of an active agent, such as a hormone, and an introducer
AU1465995A (en) N-phenyltetrahydrophthalamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient
AU688488B2 (en) Ester compound, agent for controlling noxious organisms containing the same as active ingredient, and production intermediate thereof
EP0916349A3 (en) Method for monitoring cellular oxidative function
AU666799B2 (en) N-aryloxyacyl-n-phenyltetrahydrophthalamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient
AU677262B2 (en) N-acyl-n-phenylmaleamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient
AU4135297A (en) Bicyclic hydantoin derivatives, process for producing the same, and herbicides containing the same as active ingredient
AU5455690A (en) Method for stabilizing organic phosphoric ester and soil pest controlling agent containing, as active ingredient, compound stabilized by the method
AU7431898A (en) Substituted heterocyclic nitrogens, methods for producing same and their use as pest control agent